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Case presentations
Case 1
A 61-year-old man presented with multiple small, reddish, 
eroded papules located on his chest (Figure 1A). Histo-
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Figure 1. (A) Clinical examination of case 1 showed multiple confluent erythematous papules in a patient with Grover’s disease. (B) Clini-
cally, multiple reddish papules were observed on the chest of a patient with stage IV melanoma treated with vemurafenib. (Copyright: ©2015 
Specchio et al.)
pathologic examination revealed the typical findings of 
Grover’s disease.
Case 2
A 47-year-old woman was treated with vemurafenib for stage 
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benign and malignant lesions, such as cutaneous squamous-
cell carcinoma, verrucal keratosis, plantar hyperkeratosis, 
hair follicle changes, panniculitis, and photosensitivity [2], 
along with widespread eruptions with histologic features of 
acantholytic dyskeratosis [3]. Acantholytic dyskeratoma has 
been previously reported in association with other chemo-
therapeutics, including the epidermal growth factor receptor 
inhibitor cetuximab; however, the pathogenesis of acantho-
lytic dyskeratosis is still unclear. Two hypotheses have been 
postulated. One theory is that the accumulation in the skin 
of chemotherapy metabolites by sweating may be related to 
the development of dyskeratosis and acantholysis; another 
theory supposes that acantholytic dyskeratosis may represent 
an off-target effect of small-molecule kinase inhibitors [1].
Recognition of cutaneous side effects occurring during 
BRAF-inhibitor therapy is essential for patient management. 
Acantholytic dyskeratomas can be easily diagnosed by using 
dermoscopy. In fact, in acantholytic lesions, dermoscopy 
allows the visualization of a stereotypical pattern [4], which 
also assists in the differentiation of these benign lesions from 
malignancy, such as keratoacanthoma or invasive squamous 
cell carcinoma that may also occur as a complication of 
BRAF inhibitor therapy. Typically, these papules display a 
central star-like pattern of brown scales that are otherwise 
not detectable at clinical examination. This dermoscopic 
pattern has been described to be peculiar for Grover’s disease 
and solitary acantholytic dyskeratoma [4]. Interestingly, our 
study shows the characteristic dermoscopic star-like pattern 
can be observed in acantholytic dyskeratotic lesions occur-
ring during treatment with BRAF-inhibitors, as previously 
reported [3].
In conclusion, our case underlines the importance of der-
moscopy to improve the recognition of acantholytic dyskera-
tomas (in Grover’s disease and in patients under vemurafenib 
therapy), a skin eruption that is usually difficult to diagnose 
by naked eye.
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IV melanoma, having been referred because of the recent 
onset of multiple asymptomatic reddish papules located on 
her chest (Figure 1B). These lesions represented a skin rash 
of acantholytic dyskeratoma occurring while under vemu-
rafenib treatment that spontaneously disappeared over the 
next few weeks.
The dermoscopic evaluation of the lesions in both cases 
showed a central yellowish to brown star-like pattern over-
lying a pinkish homogeneous structureless area (Figure 2A 
and B).
Conclusions
Treatment with vemurafenib, a small-molecule BRAF inhib-
itor, has led to significant improvement of prognosis in 
patients with advanced melanoma. Similar to other kinase 
inhibitors, the use of vemurafenib has been accompanied by 
several dermatologic adverse events [1]. These include both 
Figure 2. (A) Dermoscopic evaluation of case 1 displayed a central 
yellowish to brown star-like pattern overlying a pinkish homoge-
neous structureless area similarly to the ones observed in case 2 (B). 
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